Garcia, Denise
Nasarre, Patrick
Bonilla, Ingrid V.
Hilliard, Eleanor
Peterson, Yuri K.
Spruill, Laura
Broome, Anne-Marie
Hill, Elizabeth G.
Yustein, Jason T.
Mehrotra, Shikhar
Klauber-DeMore, Nancy
Funding for this research was provided by:
St. Baldwick's Foundation to JTY
Hollings Cancer Center, Medical University of South Carolina
U.S. Department of Defense (W81XWH-18-1-0007)
NIH Clinical Center (CA193201)
Sarcoma Foundation of America (R01CA138930, R21CA137725)
Cancer Prevention and Research Institute of Texas
Article History
Received: 22 March 2019
First Online: 12 September 2019
Disclosure
: Novel Targets for Regulation of Angiogenesis, US Patent No. 8,734,789. Inventor: Nancy Klauber-DeMore, MD. Combination therapy of a humanized antibody to secreted frizzled-related 2 with PD-1 inhibition for the treatment of cancer. US Provisional App. No. 62/737,155. Inventor: Nancy Klauber-DeMore, MD. Dr. Klauber-DeMore is co-founder, shareholder, Chief Scientific Officer, and Board Member of Enci Therapeutics, Inc.